- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-09-01-2021
Pharmaceutical Executive, September 2021 Issue (PDF)
September 14, 2021
Issue PDF
41
9
Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.
When Innovation Outpaces HTA, Access Struggles to Keep Up
September 14, 2021
Back Page
41
9
Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.
Doubling Down On Innovation, Recovery
September 14, 2021
Features
41
9
Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.
Developing a Product Launch Strategy for an Orphan Drug
September 14, 2021
Features
41
9
Commercializing an orphan drug can be challenging, however, using a framework and a checklist that incorporates the right elements can prove beneficial.
Investing for Success: Finding the Right Launch Balance
September 14, 2021
Features
41
9
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Rethinking Obesity: Wegovy
September 14, 2021
Features
41
9
New drug aims to turn obesity into treatable chronic condition.
Fear Factor: Palforzia
September 14, 2021
Features
41
9
Peanut allergies raise fears among parents, teachers, but treatment is now available.
Formidable Option: Orgovyx
September 14, 2021
Features
41
9
Hopeful new standard of care for advanced prostate cancer capitalizing on momentum.
No Small Feat: Nurtec ODT
September 14, 2021
Features
41
9
The aggressive strategy behind a small company’s quick ascent in migraine market.
‘Rare’ Reinforcement: Evrysdi
September 14, 2021
Features
41
9
Latest disease-modifying market entrant for SMA addresses administration, access gaps.
Serial Problem Solver
September 14, 2021
Executive Profile
41
9
Teva CEO Kåre Schultz talks about his long industry experience tackling major strategic and operational challenges, and how he is progressing on his current mission to turn around Teva’s fortunes.
Adding More Context to Biotech Headwinds
September 14, 2021
Finance
41
9
When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.
The Comeback of Unbranded Campaigns
September 14, 2021
Marketing
41
9
Vaccines spotlight recent resurgence of useful messaging tool.
Driving Digital Progress in Medical Affairs
September 14, 2021
Technology
41
9
Digital transformation in medical affairs made a sluggish start, but there is plenty to be optimistic about.
More Jobs and Less Talent Has Created an Imbalance in Pharma
September 14, 2021
Leadership
41
9
If not addressed, effects could impact innovation, diversity.
Advanced Therapy Makers Claim a Double Barrier Over Access
September 14, 2021
Global Report
41
9
Treatment availability for rare disease patients under fire in Europe.
FDA Advances New Drugs, Biosimilars
September 14, 2021
Washington Report
41
9
But accelerated approval program faces scrutiny.
Pharma Campaigns Take Center Stage
September 14, 2021
From the Editor
41
9
Pharm Exec profiles five recent drug launches and announces winners of first annual APEX Awards.
Startup Launch Guide: Avoiding 10 Common Pain Points
August 11, 2021
Features
41
9
With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.